News & Updates

Isotretinoin users do not appear to have an elevated risk of self-harm, with the risk of suicide attempts being lower at 2 to 4 years after treatment, according to the results of a meta-analysis.

Delays in postoperative radiation therapy (PORT) may lead to increased locoregional recurrence (LRR), usually occurring beyond the radiation field, among patients with Merkel cell carcinoma (MCC), as shown in a recent study.

New drug applications approved by US FDA as of 01-15 January 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-31 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The combination of oral acitretin plus topical triamcinolone acetonide (TAC) appears to have superior efficacy than TAC alone in the treatment of patients with oral lichen planus, as shown in a study.

New drug applications approved by US FDA as of 01-15 December  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.